SkyView Investment Advisors LLC Acquires Shares of 146,071 Eyenovia, Inc. (NASDAQ:EYEN)

SkyView Investment Advisors LLC acquired a new stake in Eyenovia, Inc. (NASDAQ:EYEN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 146,071 shares of the company’s stock, valued at approximately $87,000. SkyView Investment Advisors LLC owned about 0.27% of Eyenovia at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of EYEN. Armistice Capital LLC bought a new stake in Eyenovia in the second quarter worth $3,601,000. Vanguard Group Inc. lifted its holdings in shares of Eyenovia by 25.2% in the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after acquiring an additional 360,924 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Eyenovia by 1,444.4% in the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after acquiring an additional 205,390 shares during the last quarter. Ground Swell Capital LLC purchased a new position in shares of Eyenovia during the 2nd quarter worth about $27,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Eyenovia during the 2nd quarter valued at about $26,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Insider Activity at Eyenovia

In other Eyenovia news, major shareholder Stuart M. Grant bought 1,515,151 shares of the business’s stock in a transaction on Tuesday, July 2nd. The shares were acquired at an average price of $0.66 per share, with a total value of $999,999.66. Following the transaction, the insider now owns 10,914,153 shares of the company’s stock, valued at approximately $7,203,340.98. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Michael M. Rowe acquired 50,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the purchase, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Stuart M. Grant bought 1,515,151 shares of the business’s stock in a transaction on Tuesday, July 2nd. The stock was bought at an average price of $0.66 per share, for a total transaction of $999,999.66. Following the purchase, the insider now directly owns 10,914,153 shares of the company’s stock, valued at $7,203,340.98. The disclosure for this purchase can be found here. Insiders bought 1,592,222 shares of company stock worth $1,042,577 over the last three months. 7.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EYEN. William Blair raised shares of Eyenovia to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Eyenovia in a report on Tuesday, August 13th.

Eyenovia Stock Performance

Shares of NASDAQ:EYEN opened at $0.50 on Monday. The firm’s 50 day simple moving average is $0.76 and its 200-day simple moving average is $0.80. The company has a debt-to-equity ratio of 3.72, a quick ratio of 0.27 and a current ratio of 0.46. Eyenovia, Inc. has a one year low of $0.37 and a one year high of $2.57. The firm has a market cap of $26.67 million, a PE ratio of -0.66 and a beta of 1.74.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $1.38 million. As a group, equities analysts predict that Eyenovia, Inc. will post -0.57 EPS for the current year.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.